CYTK Cytokinetics Inc
4,064
$64.02
$1.25
(1.92%)
| Watchers | 4,064 |
| 52-Wk Low | $25.98 |
| 52-Wk High | $110.25 |
| Market Cap | $6.83B |
| Volume | 2.4M |
| 52-Wk High | $110.25 |
| 52-Wk Low | $25.98 |
Cytokinetics presents additional 48-week data from FOREST-HCM studyThe Fly • about 1 month ago
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Share to Feed
Treatment with Aficamten for 48 Weeks is Associated with Improvements in Clinical Efficacy Endpoints, NYHA Class and Cardiac Biomarkers, Structure and FunctionSOUTH SAN FRANCISCO, Calif., April 05...
Shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) have earned a consensus rating of "Moderate Buy" from the fifteen brokerages that are currently covering the stock, MarketBeat...
read more...
SOUTH SAN FRANCISCO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on March 29, 2024 it granted stock options to purchase an aggregate of...
Cytokinetics, Incorporated: Buyout Speculation Persists...
Cytokinetics, Incorporated: Buyout Speculation Persists...
SOUTH SAN FRANCISCO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to...
In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Cytokinetics Inc (CYTK) was identified as having a larger market cap than the smaller end of the S&P 500...
This price move could be a signal that CYTK may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options...